학술논문
A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS248-TPS248, 235p
Subject
Language
ISSN
0732183X